Ambio

What Ambio does

Ambio, Inc. is a US-based specialty pharmaceutical company (Beech Island, South Carolina; also operating as AmbioPharm) that develops peptide drugs, biosimilars, and complex generic pharmaceuticals for therapeutic use. The company builds on the legacy of its founder and CEO Chris Bai, who previously led American Peptide Company, and operates with a small team (11–50 employees) under a leadership group that includes President Simrat Singh (global operations) and CFO Rob Hughes (life-sciences finance). Ambio's stated differentiators are proprietary know-how in chemical synthesis of peptides typically produced via rDNA, a microsphere platform enabling sustained/controlled release, and advanced analytical characterization methods guided by Quality by Design principles.

The commercial portfolio consists of two products both sold through partners: Teriparatide Injection (generic Forteo, FDA-approved and US-launched in 2023 via Apotex Corp. for osteoporosis) and Icatibant (generic Firazyr, launched in 14 international markets in 2022 via Adalvo for hereditary angioedema). The pipeline extends into biosimilars for high-value targets including Semaglutide (Wegovy/Ozempic/Rybelsus), Liraglutide (Victoza/Saxenda), Octreotide (Sandostatin), Lanreotide (Somatuline Depot), Teduglutide (Gattex), Corticotropin (Acthar Gel), and Eteplirsen (Exondys 51), targeting diabetes, obesity, acromegaly, short bowel syndrome, and Duchenne muscular dystrophy.

Ambio's go-to-market is a B2B co-development model: Ambio handles development, synthesis, manufacturing scale-up, and regulatory filings, while partner pharmaceutical companies (Apotex for the US, Adalvo for international markets) commercialize, market, and distribute the approved products. Revenue is generated through development fees, regulatory and launch milestones, and licensing royalties/contract manufacturing services — Ambio does not sell directly to end markets or patients. The company has no disclosed AI/ML capabilities and no disclosed funding rounds, and operates without a parent company.

Name

Ambio

Legal name

Ambio, Inc.

Website

https://ambiorx.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

11–50 employees

Short description

Ambio, Inc. is a US specialty pharmaceutical company that develops peptide drugs, biosimilars, and complex generic pharmaceuticals for large pharmaceutical partners (Apotex, Adalvo) who handle commercialization and distribution. It targets diabetes, obesity, osteoporosis, and rare-disease indications through a co-development-and-licensing model.

Ownership category

akta.pro rank

Headquarters

HQ city

Beech Island

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Infrastructure, Operations

Revenue model

1. Co-development Partnerships: Ambio develops generic versions of branded peptide drugs in partnership with pharmaceutical companies. Revenue is generated through development fees, regulatory approval milestones, and product launch fees from partners like Apotex and Adalvo.
2. Contract Manufacturing Services: Provides peptide development and manufacturing services to pharmaceutical partners. The company transfers small lab scale processes to large scale commercial manufacturing.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Ambio is a specialty pharmaceutical company that develops peptide drugs, biosimilars, and complex generic pharmaceuticals through proprietary chemical synthesis and microsphere platform technologies. The company operates on a co-development model, developing peptide therapeutics (such as generic Forteo/Teriparatide and generic Firazyr/Icatibant) that are commercialized by pharmaceutical partners like Apotex in the U.S. and Adalvo internationally. Ambio also offers peptide development and manufacturing services, scaling processes from lab to commercial production.

Product overview

Ambio is a specialty pharmaceutical company offering a unified portfolio of peptide drug development and manufacturing services and products. The core offering consists of proprietary chemical synthesis, microsphere delivery platform, and complex peptide characterization technologies. Their commercial products include Teriparatide Injection (generic Forteo for osteoporosis, FDA-approved 2023) and Icatibant (generic Firazyr for hereditary angioedema, launched 2022). The pipeline includes biosimilar peptides targeting blockbuster indications in diabetes (Liraglutide, Semaglutide, Teduglutide), obesity (Semaglutide, Liraglutide), osteoporosis (Teriparatide), and specialty areas (Octreotide, Lanreotide, Corticotropin, Eteplirsen). The company operates through exclusive co-development partnerships with pharmaceutical companies like Apotex and Adalvo.

Differentiator

Problem solved

Functional benefit

Products and services

• Teriparatide Injection (Generic Forteo) Generic peptide drug equivalent to Eli Lilly's Forteo (teriparatide), indicated for osteoporosis treatment. Developed by Ambio and marketed/sold in the U.S. by Apotex. Single-patient-use pre-filled pen delivering 28 daily doses.
• Icatibant (Generic Firazyr) Selective bradykinin B2 receptor antagonist used to treat acute attacks of hereditary angioedema (HAE), a serious orphan disease. Equivalent and more affordable version of Firazyr (Takeda/Shire). Launched in 14 international markets through partner Adalvo.
• Peptide Drug Development Services End-to-end peptide drug development and manufacturing services for pharmaceutical partners, including R&D, process development, scale-up from lab to commercial manufacturing, and analytical characterization. Offered via co-development partnerships.
• Liraglutide (Victoza/Saxenda) Biosimilar peptide targeting GLP-1 receptor for treatment of type 2 diabetes (Victoza) and obesity (Saxenda). In development pipeline.
• Semaglutide (Wegovy/Rybelsus/Ozempic) Biosimilar peptide targeting GLP-1 receptor for treatment of type 2 diabetes (Ozempic, Rybelsus) and obesity (Wegovy). In development pipeline.
• Octreotide (Sandostatin) Biosimilar peptide targeting somatostatin receptors (generic equivalent of Sandostatin). In development pipeline.
• Lanreotide (Somatuline Depot) Biosimilar peptide for treatment of acromegaly and neuroendocrine tumors. In development pipeline.
• Teduglutide (Gattex) Biosimilar peptide for treatment of short bowel syndrome. In development pipeline.
• Corticotropin (Acthar Gel) Biosimilar peptide (ACTH) for various therapeutic applications. In development pipeline.
• Eteplirsen (Exondys 51) RNA therapy for treatment of Duchenne muscular dystrophy (DMD). In development pipeline.

Named customers2 records

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Apotex Corp.coreStrategic or Co-development Partner · 1 November 2023Apotex is Ambio's exclusive co-development partner for Teriparatide Injection (generic version of Forteo). Ambio developed the product and Apotex markets and sells it to the U.S. healthcare market. The product received FDA approval in December 2023 and was launched immediately. Apotex is a US-based company headquartered in Weston, Florida, and a leader in generic pharmaceuticals and biosimilars.
• AdalvocoreStrategic or Co-development Partner · 1 January 2022Adalvo is a strategic partner of Ambio for the development, synthesis, and manufacturing of complex injectable peptide products. Ambio worked in close collaboration with Adalvo on Icatibant, an equivalent version of Firazyr (Takeda/Shire) for hereditary angioedema treatment. Icatibant was successfully launched in 14 markets worldwide.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Aurobindo Pharma: Large Indian generic and biosimilar pharmaceutical manufacturer with growing peptide and biosimilar portfolio including GLP-1 programs. Overlaps with Ambio in target indications (semaglutide/liraglutide biosimilars) but operates at much greater scale across many therapeutic categories.
• Samsung Bioepis: Samsung-backed biosimilar developer commercializing multiple biosimilars globally. Adjacent to Ambio in pipeline focus (chronic disease biosimilars) and partnership-distribution model but with broader approved portfolio.
• Celltrion: South Korean biosimilar developer with leading approved biosimilars and active peptide/biosimilar pipeline. Competes with Ambio for similar biosimilar opportunities, particularly in oncology supportive care and chronic disease, but operates at significantly larger scale.
• Cipla: Indian multinational generic and specialty pharma with active peptide and biosimilar development programs. Comparable to Ambio in target indications and partner-led commercialization, but operates at substantially larger scale across multiple categories.
• Teva Pharmaceutical Industries: Global generic and specialty pharma leader with a significant peptide franchise. Competes with Ambio for biosimilar opportunities in osteoporosis, oncology supportive care, and rare diseases, but operates a vastly broader portfolio.

Direct peers

• Bachem: Swiss-based world leader in peptide CDMO services and manufacturing. Directly comparable to Ambio along product offering (peptide synthesis and manufacturing), customer base (pharmaceutical partners), and underlying chemistry (peptide manufacturing with tight impurity control).
• Lotus Pharmaceutical: Specialty generic injectable pharma with peptide injectable focus. Comparable to Ambio in product category (complex injectable generics), target therapeutic areas (oncology supportive care, osteoporosis), and partner-distribution commercialization approach.
• ScieGen Pharmaceuticals: U.S. specialty generic injectable pharma focused on complex generics including peptides. Closely aligned with Ambio in product category (complex injectable generics), target customers (generic and specialty pharma distribution), and FDA-driven business model.
• Polypeptide Group: Specialized peptide CDMO offering custom synthesis and GMP manufacturing for peptide APIs. Comparable to Ambio across technology platform, manufacturing focus, and pharmaceutical partner customer model.

Others

• Adalvo: Strategic partner of Ambio — also operates as a specialty generic pharma distributor/developer. Comparable to Ambio in product focus (complex injectable generics) and target markets, but functions as a partner rather than direct competitor for Ambio's co-developed assets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/ambiorx

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ambio